Previous 10 | Next 10 |
Fennec Pharmaceuticals (NASDAQ: FENC ) -31% on FDA rejection of Pedmark application. More news on: Fennec Pharmaceuticals Inc., Mesoblast Limited, Genesis Healthcare, Inc., Stocks on the move, , Read more ...
CORAL GABLES, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) : Q2 GAAP EPS of $0.09 in-line. Revenue of $29.6M (+2.6% Y/Y) beats by $0.12M . Research and development expenses $4.3M vs. $4.6M in 2Q19. Shares -18% . Press Release More news on: Catalyst Pharmaceuticals, Inc., Earnings news and comme...
- Firdapse ® Second Quarter Net Revenues of $29.6 Million - Health Canada Approves Marketing Authorization for Firdapse ® for Treating LEMS Patients - MuSK-MG Phase 3 Trial did not Achieve Statistical Significance for Primary or Secondary Endpoints - Company to Hos...
It's become conventional wisdom on Wall Street that the Robinhood trading platform is a playground for young, inexperienced day traders chasing the quick buck -- so-called "dumb money" following the latest trend. Well, maybe experienced investors shouldn't be so quick to judge. A report by Gol...
Introduction To keep myself sharp and my skills honed, I routinely go to my library of investment books and re-read classics that have had an impact on me. This week, I did a complete re-read of Joel Greenblatt's classic "The Little Book That Beats The Market." For any of you that are not ...
CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...
Immunic announced positive top line data for IMU-838 Immunic Inc. ( IMUX ) announced top line data from Phase EMPhASIS trial of lead drug candidate, IMU-838, aimed at patients with relapsing-remitting multiple sclerosis or RRMS. The company reported that the trial achieved all its primar...
CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...
CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...